<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>Insight数据库 | wechat-feeds</title><link>http://MzA4MzkzMDYyNw.favicon.privacyhide.com/favicon.ico</link><description>丁香园 Insight 数据库（db.dxy.cn），拥有申报、临床、上市、药企等 10 大核心数据。致力于分享医药行业政策解读、药企大事和药品申报情报等</description><managingEditor> (hellodword)</managingEditor><pubDate>Wed, 09 Jun 2021 11:46:55 +0800</pubDate><image><url>http://MzA4MzkzMDYyNw.favicon.privacyhide.com/favicon.ico</url><title>Insight数据库 | wechat-feeds</title><link>http://MzA4MzkzMDYyNw.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>重磅！首个国产 ADC 荣昌生物「纬迪西妥单抗」附条件批准上市</title><link>https://mp.weixin.qq.com/s/YOjwewCEWQJ4c_YoeCa6ww</link><description></description><content:encoded><![CDATA[重磅！首个国产 ADC 荣昌生物「纬迪西妥单抗」附条件批准上市]]></content:encoded><pubDate>Wed, 09 Jun 2021 09:52:05 +0800</pubDate></item><item><title>刚刚！泽璟制药 1 类新药「甲苯磺酸多纳非尼片」正式获批</title><link>https://mp.weixin.qq.com/s/6Nj6D3M_-4AP2FZ7LQIZjA</link><description></description><content:encoded><![CDATA[刚刚！泽璟制药 1 类新药「甲苯磺酸多纳非尼片」正式获批]]></content:encoded><pubDate>Wed, 09 Jun 2021 09:52:05 +0800</pubDate></item><item><title>从 KRAS G12C 抑制剂看中国本土 Biotech 研发实力</title><link>https://mp.weixin.qq.com/s/7dWuLivmnPpwBV-MkriBNQ</link><description></description><content:encoded><![CDATA[从 KRAS G12C 抑制剂看中国本土 Biotech 研发实力]]></content:encoded><pubDate>Tue, 08 Jun 2021 19:07:41 +0800</pubDate></item><item><title>一线治疗鼻咽癌！恒瑞 PD-1 新适应症即将获批</title><link>https://mp.weixin.qq.com/s/P7rhbfORXaqjiB3yv2LYHg</link><description></description><content:encoded><![CDATA[一线治疗鼻咽癌！恒瑞 PD-1 新适应症即将获批]]></content:encoded><pubDate>Tue, 08 Jun 2021 19:07:41 +0800</pubDate></item><item><title>百济神州泽布替尼新适应症即将获批，华氏巨球蛋白血症</title><link>https://mp.weixin.qq.com/s/wxRkXstZOldPvurF8yQu3g</link><description></description><content:encoded><![CDATA[百济神州泽布替尼新适应症即将获批，华氏巨球蛋白血症]]></content:encoded><pubDate>Tue, 08 Jun 2021 19:07:41 +0800</pubDate></item><item><title>君实任命钱巍先生为首席商务官</title><link>https://mp.weixin.qq.com/s/84cSIy8zrEWfQSDPIQwxgQ</link><description></description><content:encoded><![CDATA[君实任命钱巍先生为首席商务官]]></content:encoded><pubDate>Tue, 08 Jun 2021 19:07:41 +0800</pubDate></item><item><title>渤健/卫材阿尔兹海默病新药获 FDA 批准，国内仅恒瑞在研</title><link>https://mp.weixin.qq.com/s/4h_QTu_Jfph-NWtSqdn9pA</link><description></description><content:encoded><![CDATA[渤健/卫材阿尔兹海默病新药获 FDA 批准，国内仅恒瑞在研]]></content:encoded><pubDate>Tue, 08 Jun 2021 19:07:41 +0800</pubDate></item><item><title>首个国产 ADC 即将获批！荣昌生物纬迪西妥单抗进入行政审批阶段</title><link>https://mp.weixin.qq.com/s/0raPA8-R1Xa0iZWEdzzC-g</link><description></description><content:encoded><![CDATA[首个国产 ADC 即将获批！荣昌生物纬迪西妥单抗进入行政审批阶段]]></content:encoded><pubDate>Mon, 07 Jun 2021 17:06:18 +0800</pubDate></item><item><title>和记黄埔 1 类新药「索凡替尼」新适应症即将获批</title><link>https://mp.weixin.qq.com/s/zlgXssPvyihhoU2Rwa07tw</link><description></description><content:encoded><![CDATA[和记黄埔 1 类新药「索凡替尼」新适应症即将获批]]></content:encoded><pubDate>Mon, 07 Jun 2021 17:06:18 +0800</pubDate></item><item><title>68 周减重18%！诺和诺德「司美格鲁肽」减肥适应症获 FDA 批准上市</title><link>https://mp.weixin.qq.com/s/27UrUvMXL55_U0-xrW70jg</link><description></description><content:encoded><![CDATA[68 周减重18%！诺和诺德「司美格鲁肽」减肥适应症获 FDA 批准上市]]></content:encoded><pubDate>Mon, 07 Jun 2021 17:06:18 +0800</pubDate></item><item><title>国内首个「德谷门冬双胰岛素」生物类似药获批临床</title><link>https://mp.weixin.qq.com/s/R7DDBrn77A3a29X1IoQIXg</link><description></description><content:encoded><![CDATA[国内首个「德谷门冬双胰岛素」生物类似药获批临床]]></content:encoded><pubDate>Mon, 07 Jun 2021 17:06:18 +0800</pubDate></item><item><title>我国新冠疫苗紧急使用年龄扩大到 3 岁以上</title><link>https://mp.weixin.qq.com/s/VDyGLiOGW7VxdbP1VcHqxg</link><description></description><content:encoded><![CDATA[我国新冠疫苗紧急使用年龄扩大到 3 岁以上]]></content:encoded><pubDate>Mon, 07 Jun 2021 17:06:18 +0800</pubDate></item><item><title>科伦药业最新会议纪要</title><link>https://mp.weixin.qq.com/s/8vvL54Q8sw5mjFv188zWYQ</link><description></description><content:encoded><![CDATA[科伦药业最新会议纪要]]></content:encoded><pubDate>Mon, 07 Jun 2021 17:06:18 +0800</pubDate></item><item><title>国内上市药品、在研新药查询这么简单了！还有人死盯着官网不放？</title><link>https://mp.weixin.qq.com/s/Y84AAbDcYkcL6CCca-_oFA</link><description></description><content:encoded><![CDATA[国内上市药品、在研新药查询这么简单了！还有人死盯着官网不放？]]></content:encoded><pubDate>Fri, 04 Jun 2021 22:06:08 +0800</pubDate></item><item><title>中国智造闪耀国际舞台！替雷利珠单抗多项研究成果亮相 ASCO 2021</title><link>https://mp.weixin.qq.com/s/YB_uMid6u-8fyXltDdCGDA</link><description></description><content:encoded><![CDATA[中国智造闪耀国际舞台！替雷利珠单抗多项研究成果亮相 ASCO 2021]]></content:encoded><pubDate>Fri, 04 Jun 2021 22:06:08 +0800</pubDate></item><item><title>全球首个 KRAS 靶向药获批上市，哪些患者获益最大？</title><link>https://mp.weixin.qq.com/s/QOJ1OJCitiAYdY4eP7DqsA</link><description></description><content:encoded><![CDATA[全球首个 KRAS 靶向药获批上市，哪些患者获益最大？]]></content:encoded><pubDate>Fri, 04 Jun 2021 22:06:08 +0800</pubDate></item><item><title>CAR-T 疗法进展迅猛，实体瘤、通用型、多靶点又有新进展！</title><link>https://mp.weixin.qq.com/s/WJWShCoGCnwwnh2vUR5_8Q</link><description></description><content:encoded><![CDATA[CAR-T 疗法进展迅猛，实体瘤、通用型、多靶点又有新进展！]]></content:encoded><pubDate>Fri, 04 Jun 2021 16:33:32 +0800</pubDate></item><item><title>刚刚！百济神州 PD-1 新适应症上市申请获受理</title><link>https://mp.weixin.qq.com/s/hwVIqwJTeU2P6zjHGdmbug</link><description></description><content:encoded><![CDATA[刚刚！百济神州 PD-1 新适应症上市申请获受理]]></content:encoded><pubDate>Fri, 04 Jun 2021 16:33:32 +0800</pubDate></item><item><title>恒瑞「吡咯替尼」联合曲妥珠单抗加化疗乳腺癌 III 临床成功</title><link>https://mp.weixin.qq.com/s/sp_wFZYMwcmHBAIUs1sJ2A</link><description></description><content:encoded><![CDATA[恒瑞「吡咯替尼」联合曲妥珠单抗加化疗乳腺癌 III 临床成功]]></content:encoded><pubDate>Fri, 04 Jun 2021 16:33:32 +0800</pubDate></item><item><title>君实生物 CTLA-4 单抗获批临床</title><link>https://mp.weixin.qq.com/s/wi1XwwvY-deC_SxbmF05JQ</link><description></description><content:encoded><![CDATA[君实生物 CTLA-4 单抗获批临床]]></content:encoded><pubDate>Fri, 04 Jun 2021 16:33:32 +0800</pubDate></item></channel></rss>